News

GNC elects president, CEO to chairman of the company’s board

BY Michael Johnsen

PITTSBURGH — GNC Holdings on Friday elected company president and CEO Joseph Fortunato to serve as chairman. The board also has appointed Michael Hines to serve as lead independent director.

Fortunato succeeds Norman Axelrod, who has resigned as chairman. Axelrod had been a member of the GNC board since March 2007.

"We would like to thank Norman for his distinguished service as [chairman]," Fortunato stated. "Norman’s strong and dedicated leadership has been instrumental in guiding the company through a pivotal transition period, including a successful IPO, and in shaping the strategic vision that has positioned GNC for continued growth in the near- and long-term future."

GNC expects to announce a replacement for Axelrod’s seat on the board shortly, the company stated.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

iWatchz introduces watch bands for iPod Nano

BY Allison Cerra

NEW YORK — A line of watch bands that allows users to sport their iPod Nano like a watch has hit retail.

iWatchz offers nine collections of Nano watch bands, all of which tout the iWatchz patent-pending clip system, offering a snug and secure fit for the iPod Nano. The bands range from vibrant silicone to soft-touch leather to stainless steel links to cater to every style-conscious music lover, the company said.

Retailing for $24.99 and up, iWatchz Nano watch bands are available at various stores, including Target, Apple, Best Buy, Amazon.com and iWatchz.com.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Pfizer pain drug doesn’t affect sperm production, study finds

BY Alaric DeArment

NEW YORK — A drug made by Pfizer for treating pain disorders doesn’t affect men’s reproductive functions, according to a new post-approval clinical study.

The drug maker announced Monday the results of study A0081104 of Lyrica (pregabalin), which compared the drug with placebo in healthy males to assess its effects on sperm production. The phase-4 study was required by the Food and Drug Administration.

The study enrolled 222 men, who were randomly selected to receive either the drug or placebo. Lyrica is used to treat post-herpetic neuralgia, diabetic nerve pain, fibromyalgia, neuropathic pain associated with spinal cord injury and partial-onset seizures in certain adults with epilepsy.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?